<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01171105</url>
  </required_header>
  <id_info>
    <org_study_id>D3030C00002</org_study_id>
    <nct_id>NCT01171105</nct_id>
  </id_info>
  <brief_title>Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects</brief_title>
  <official_title>A Phase I, Double-blind, Randomized, Placebo-controlled', Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD5213 After Administration of Multiple Ascending Doses for 10 Days in Healthy Male and Non-fertile Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. The main purpose of this study is to assess the safety and tolerability of AZD5213 after
           multiple oral doses.

        2. Another purpose of this study is to evaluate the pharmacokinetics (also called PK - how
           the study drug enters and leaves your body and how your body acts on the study drug) of
           AZD5213 in your blood and urine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, vital signs, physical (including neurological) examinations, clinical laboratory variables, electrocardiograms, telemetry, sleep diary (temporal and qualitative aspects), and the Columbia-Suicide Severity Rating Scale</measure>
    <time_frame>Up to 30 days screening period. Residential period will be 14 days. Follow up period will be 7 to 10 days after dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose PK and dose proportionality</measure>
    <time_frame>Frequent timepoints within 48 hours of multiple dose day 1 and day 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach steady state</measure>
    <time_frame>Frequent timepoints within 48 hours of multiple dose day 1 and day 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of accumulation and time dependancy of orally-administered AZD5213</measure>
    <time_frame>Frequent timepoints within 48 hours of multiple dose day 1 and day 12.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5213 (dose escalating)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5213</intervention_name>
    <description>oral solution, multiple ascending doses</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to AZD5213</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and non-fertile female healthy volunteers aged 18-50 years and 65-80 years
             inclusive at day of enrollment with suitable veins for cannulation or repeated
             venipuncture.

          -  Male healthy volunteers should be willing to use barrier contraception during sexual
             intercourse, ie condoms, even if partner is using contraceptive method, from the first
             day of dosing until 3 months after the last dosing with AZD5213.

          -  Body weight of ≥50 to ≤100 Kg and Body Mass Index (BMI) ≥18 to ≤30 kg/m2.

        Exclusion Criteria:

          -  History and presence of any clinically significant disease or disorder such as
             cardiovascular, pulmonary, renal, hepatic, neurological, gastrointestinal and
             psychiatric/mental disorders.

          -  History or presence of gastrointestinal (including irritable bowel disease), hepatic
             or renal disease or any other condition known to interfere with absorption,
             distribution, metabolism, or excretion of drugs. Surgery on gastrointestinal tract.

          -  History of previous or ongoing psychiatric disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Mathews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, 6700 W. 115th Street, Overland Park, KS 66211</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1313&amp;filename=D3030C00002_Clinical_Study_Report_Synopsis.pdf</url>
    <description>D3030C00002 Clinical Study Report Synopsis</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2010</study_first_submitted>
  <study_first_submitted_qc>July 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2010</study_first_posted>
  <last_update_submitted>January 27, 2015</last_update_submitted>
  <last_update_submitted_qc>January 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD5213 Phase 1</keyword>
  <keyword>Safety</keyword>
  <keyword>tolerability</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

